Fate of oral enzymes in pancreatic insufficiency

Please download to get full document.

View again

of 5
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information Report
Category:

Internet

Published:

Views: 0 | Pages: 5

Extension: PDF | Download: 0

Share
Related documents
Description
708 Fate of oral enzymes in pancreatic insufficiency Gut 1993; 34: Digestive System Research Unit, Hospital General Vail d'hebron, Autonomous University of Barcelona, Spain L Guarner R Rodriguez
Transcript
708 Fate of oral enzymes in pancreatic insufficiency Gut 1993; 34: Digestive System Research Unit, Hospital General Vail d'hebron, Autonomous University of Barcelona, Spain L Guarner R Rodriguez F Guarner J-R Malagelada Correspondence to: Dr Luisa Guarner, Digestive System Research Unit, Hospital General Vail d'hebron, Barcelona, Spain. Accepted for publication 22 September 1992 L Guarner, R Rodriguez, F Guarner, J-R Malagelada Abstract Oral pancreatic enzyme supplements, including those protected from gastric acidity by enteric coating, often achieve only partial correction of pancreatic steatorrhoea. To characterise the mechanisms involved in vivo, eight patients with steatorrhoea due to advanced pancreatic insufficiency and nine healthy controls were studied. Two sets of studies (smali bowel intubation and five day faecal fat quantification) were randomly performed while patients were either on enteric coated pancreatin or equivalent placebo. A 260 cm long multilumen tube was used for double marker perfusion of two 20 cm segments located in the duodenum and in the ileum respectively. Luminal ph, flow, and trypsin and lipase activity outputs were measured at each segment for four hours postcibally. Placebo treated patients with pancreatic steatorrhoea had low enzyme outputs in the duodenal test segment and even lower outputs in the ileal segment. Pancreatin treatment significantly decreased steatorrhoea (p 005) and increased luminal enzyme outputs (p 005). The increase was much greater in the ileal than in the duodenal segment. Thus enteric coated pancreatin treatment abolished the normal gradient between postcibal duodenal and ileal lipase output. The results suggest that enteric coated pancreatin nearly corrects severe pancreatic steatorrhoea. The ingested lipase was utilised inefficiently, however, as luminal enzyme activity in the ileum was enhanced to a greater extent than in the duodenum, and consequently the absorptive potential of the small bowel was only partially utilised. (Gut 1993; 34: ) Patients with steatorrhoea due to advanced pancreatic insufficiency have extremely low duodenal pancreatic enzyme outputs (usually less than 5% of maximal output).' Oral replacement with pancreatic enzyme extracts (hereafter referred to as pancreatin) is a valuable form of treatment but complete abolition of steatorrhoea is not always achieved. Thus a number of approaches to improve the efficiency of enzyme replacement therapy have been investigated. These include lipase enrichment of pancreatin2 and coadministration of H2 blockers or omeprazole to prevent acid inactivation of enzymes (particularly lipase) and duodenal precipitation of non-ionised bile acids. Enteric coating of pancreatin into microspheres (1-2 mm) was also developed to protect enzymes from gastric acid without recourse to cotreatment with adjuvant medication.7'8 Full normalisation of fat absorption in every patient remains unachievable, however. The precise reason why enteric coated enzyme preparations fail to perform as well in clinical practice as would be theoretically expected is an intriguing and important question. Delayed gastric emptying of the microspheres has been identified as a contributary factor9 but other factors may participate. Studies in healthy subjects indicate that pancreatic hydrolytic activity (and hence the potential for nutrient digestion and absorption) is present along the entire small bowel.101' Lipase activity in the distal ileum is low, however, suggesting that enteric conservation of lipase is precarious even under physiological conditions and that little of it is wasted into the colon.'2 The prevailing view is that interactions among lipase degradation by proteolytic enzymes, luminal mixing of chyme and secretions, and small bowel transit time probably determine the efficiency by which lipase secreted postcibally by the pancreas is utilised for optimal fat digestion and absorption in the human small bowel. Our hypothesis was that patients with advanced pancreatic insufficiency, who are treated with enteric coated pancreatin, fail to optimally utilise it because the distribution of enzyme activity along the small bowel is caudally displaced by comparison with healthy subjects. Thus enzyme activity would be inappropriately low in the duodenum (where enteric coat dissolution should take place) and inappropriately high in the ileum (where enzyme wasting into the colon becomes inevitable). Our aim was to test this hypothesis by measuring, by a multiple marker perfusion technique, postcibal pancreatic enzyme activity (concentration and output) at two extremes of the small bowel in patients with pancreatic steatorrhoea who were treated with either enteric coated pancreatin or with a placebo. Healthy volunteers were similarly studied to establish normal small bowel enzyme profiles under the conditions of the study. Material and methods PATIENT MATERIAL We studied eight patients with steatorrhoea due to advanced pancreatic insufficiency and nine healthy controls. All patients (seven males and one female) had chronic alcoholic pancreatitis diagnosed clinically and confirmed in every patient by computed tomography scan and pancreatography. Moreover, all patients had abnormally low serum trypsin concentrations (range 20 to 100 ng/ml, normal 140 ng/ml) and high faecal fat excretion (range 14 2 to 46 3 g/ day, normal 7 g/day). None were active Fate oforal enzymes in pancreatic insufficiency 709 alcoholic patients at the time of study. Six of the eight were diabetic patients requiring insulin. Nine healthy volunteers (six males and three females) were also studied. Patients and volunteers gave written informed consent. The protocol for the study had been previously approved by our Institutional Review Board. PROCEDURE All patients underwent two different experimental procedures: perfusion studies and five day faecal fat balance studies. Healthy controls only underwent perfusion studies. The perfusion studies were performed as follows. After an overnight fast participants were intubated under fluoroscopic control with a 260 cm long five lumen polyvinyl tube. Two of the lumens (outside diameter (OD) 1-0 mm, inside diameter (ID) 0-5 mm) were used for infusion and two others (OD 1-9 mm, ID 1-4 mm) for aspiration. The fifth channel had radiopacque walls and was connected to a small inflatable balloon at the tip of the tube. The aspiration ports were located near the tip of the tube and 130 cm proximal to it. The infusion ports were located 20 cm proximally to each of the aspiration ports. Once the tip of the tube had advanced through the pylorus, the caudal balloon was inflated with 15 ml of air to facilitate progression of the tube along the small bowel. When it reached the distal ileum, the balloon was deflated and the position of the tube adjusted (by gentle withdrawal if necessary) so that the proximal perfusion port was in mid-duodenum just distal to the papilla of Vater. Participants then lay comfortably on a bed, head up about 45 degrees and the perfusion began. Two saline solutions (0-15 M NaCl) were simultaneously infused at 5 ml/min via the proximal and distal ports. Phenol red (250 mg/l) was added as a non-absorbable marker to the duodenal perfusate and polyethylene glycol (4.000 (5 g/l) to the ileal perfusate. After a 30 minute equilibration period a standard test meal was fed to the participants while the perfusion continued for a further 4 hour period. The four hour duration of the study was established on the basis of previous studies' 13 showing that postcibal enzyme output had usually returned to baseline after such an interval. The 500 ml liquid test meal contained 60 g of carbohydrates, 20 g of protein, and 20 g of lipids (Pentaset Standard, Nutricia, Zoetermeer, The Netherlands). Caloric proportions were 48, 16, and 36% respectively. The test meal was drunk by the participants within a 10 minute interval. Pancreatin or placebo capsules were administered with the meal. Pancreatin was administered as five capsules of a commercial enteric coated preparation. Each capsule contained FIP lipase, FIP amylase, and 450 FIP trypsin and chymotrypsin (Kreon, Kalichemie, Hannover, Germany), as verified in each batch of supplies. Intestinal contents were recovered from both aspiration ports by siphoning aided by gentle suction when needed. Aspirates were pooled over ice at 30 minute intervals, care being taken to remove no more than 10 ml during each interval to prevent depletion of chyme at the proximal port. From each of the nine pooled samples obtained from each site (one preprandial and eight postprandial) aliquots were separated for later analysis. All samples were stored at -20 C and assayed for lipase and trypsin within one to four days after the study. Under these conditions maximal loss of enzyme activity does not exceed 15%. All samples from each study were analysed on the same day. The five day fat balance study was conducted as follows. Patients were admitted to the gastroenterology ward and fed a standard diet containing 100 g of fat per day. Stools were collected for two consecutive days after three full days on the fat diet. Stools were packed in sealed containers for later analysis. In each patient two five day fat balance studies were randomly performed while they were receiving either pancreatin or placebo (five capsules with each of three daily meals). ANALYTICAL PROCEDURES AND CALCULATIONS Phenol red concentration was determined colorimetrically in duodenal samples and polyethylene glycol concentration in ileal samples. 14 Marker concentration was also measured in the corresponding perfusates. ph was measured by a glass electrode in all intestinal aspirates. Trypsin and lipase activities were measured in all duodenal and ileal samples by titrimetric methods we have previously employed and expressed in Units. The conversion factor for each enzyme activity is as follows: 1 lipase Unit=5 3 FIP, 1 trypsin Unit= 1 FIP. Faecal fat was measured by the standard gravimetric method'7 and expressed as g fat excreted in stools per 24 hours. Trypsin and lipase outputs per 30 minute period were calculated for the duodenal and ileal perfusion segments by the formula'5: Enzyme output= [Enzy.sp] x [Marki] xvolin [Markaspi where [Enzyasp]=enzyme (either trypsin or lipase) activity in the aspirate; [Markn] = concentration of either polyethylene glycol or phenol Figure 1: Cumulative postcibal trypsin outputs measured at the duodenal and ileal sites in healthy controls and in patients with pancreatic steatorrhoea with and without pancreatin treatment. Note logarithmic scale. See text for statistical analysis ofthese results. 710 Guarner, Rodriguez, Guarner, Malagelada a) C-,u s o cn 0. CD ic Duodenum r n Ir I [L,,,u,i :a CN ;t 35. ~~~~tm m30- Placebo Pancreatin 4-20 Cu Figure 2: Cumulative postcibal lipase outputs measured at the 0) m0 15* U- duodenal and ileal sites in healthy controls and in patients with pancreatic steatorrhoea with and without pancreatin 10- treatment. Note logarithmic scale. See textfor statistical analysis ofthese results. 5- red in the infusate; [Markasp] =concentration of either polyethylene glycol or phenol red in the aspirate; Volm,=volume of the marker solution perfused during each 30 minute interval. STATISTICAL ANALYSIS Trypsin and lipase outputs are expressed as means (standard error (SE) per period. Cumulative postprandial trypsin and lipase outputs were compared by calculating areas under each individual profile curve by the trapezoidal rule. Faecal fat excretion per 24 hours is expressed as mean (SE). ph data are expressed as median values (interquartiles). Comparisons between groups were performed by the Student t test (paired for placebo v pancreatin and unpaired for patients v healthy controls). Comparisons between groups for ph data were performed by the Mann-Whitney U test. Results POSTCIBAL DUODENAL AND ILEAL OUTPUTS OF PANCREATIC ENZYMES IN HEALTHY SUBJECTS In healthy subjects substantial amounts of enzymatic activity were present in the small bowel. Much higher outputs of both trypsin and 8.5 U Duodenum E 6Ileum II E 5 L Uv. Placebo Pancreatin Figure 3: Postcibal luminal ph measured in samplesfrom the duodenal and ileal sites in healthy controls and patients with pancreatic steatorrhoea with and without pancreatin treatment. Median values and upper interquartiles are presented. See text for statistical analysis ofthe results. 501 T25 fll Placebo O Pancreatin Figure 4: Faecalfat excretion measured by the 5 day standard fat balance in patients with pancreatic steatorrhoea with and without pancreatin treatment. Individual values are represented. The difference between placebo and pancreatin is statistically significant (p ooi). lipase were measured, however, in the duodenum than in the distal ileum. For trypsin, the cumulative four hour duodenal output was about twofold greater than the ileal output (p 0 05 (Fig 1)). For lipase, the duodenal output was five times higher than the corresponding ileal output (p 005 (Fig 2)). The output profiles for both enzymes at each intestinal test site were similar suggesting that regional differences in enzyme output were consistent throughout the experimental observation period. Thus our results confirm that in normal subjects there is a significant loss of luminal enzymatic activity along the small bowel and that the magnitude of such loss is considerably greater for lipase than for trypsin. POSTCIBAL DUODENAL AND ILEAL ENZYME OUTPUTS IN UNTREATED PATIENTS WITH PANCREATIC STEATORRHOEA In placebo treated patients with pancreatic steatorrhoea extremely low postcibal outputs of trypsin and lipase activity were detected in the duodenum. Duodenal outputs were - as expected given the steatorrhoea that all patients presented' - well below 5% of equivalent outputs in healthy subjects, but some enzymatic activity was measurable in every patient. In the distal ileum enzyme outputs were even lower than in the duodenum and, for lipase, activity became undetectable in six out of the eight patients; this suggests that, at least in these particular patients, whatever lipolytic capacity they were able to produce became exhausted as chyme progressed towards the caudad region of their small bowel. Ileal trypsin outputs represented about the same fraction of duodenal output, however, in patients with pancreatic insufficiency as in healthy controls (about 50% in both groups). Thus interestingly, the process of enzyme degradation along the small bowel (at least for trypsin) seems to be similar in severe hypsecretors and in healthy normosecretors. Fate oforal enzymes in pancreatic insufficiency POSTCIBAL DUODENAL AND ILEAL ENZYME OUTPUTS IN PATIENTS WITH PANCREATIC STEATORRHOEA TREATED WITH PANCREATIN In pancreatin treated patients, duodenal trypsin and lipase outputs increased by comparison with placebo treatment. The increase was modest and in only two of the eight patients total duodenal outputs (exogenous plus endogenous enzyme activity) exceeded 5% of normal outputs (as determined in the healthy controls). By contrast, in the distal ileum the increase in trypsin and lipase outputs in pancreatin treated patients was relatively much greater. Not only did it exceed by severalfold (more so in the case of lipase) the ileal outputs in placebo treated patients (p 005) but pancreatin treatment also abolished the normal gradient between duodenal and ileal lipase output. That is, ileal lipase output became similar to duodenal output (Fig 2). POSTCIBAL PH OF DUODENAL AND ILEAL CONTENTS In healthy subjects, the ph of duodenal chyme fluctuated around whereas ileal ph fluctuated at a significantly higher level around (p 005) (Fig 3). In placebo treated patients duodenal ph was slightly lower than in healthy controls. Median four hour postcibal chyme ph was below 6 in four out of eight patients with pancreatic insufficiency as opposed to only one in nine healthy controls. Ileal ph in both placebo and pancreatin treated patients was significantly higher than duodenal ph (p 0 05 (Fig 3)). Ileal ph, by analogy with duodenal ph, was lower in patients with pancreatic insufficiency than in healthy controls (p 0 05) suggesting that acidity of chyme in the patient group was abnormally high along the entire small bowel. Pancreatin treatment did not appreciably change ph either in the duodenum or in the ileum. FAECAL FAT EXCRETION IN TREATED AND UNTREATED PATIENTS WITH PANCREATIC STEATORRHOEA Placebo treated patients had an average daily faecal fat excretion of 30-2 (4 5) g (Fig 4). During pancreatin treatment faecal fat excretion fell to 11-6 (2 3) g/24 hours (p 0 01). There was no apparent correlation between improvement in fat absorption during pancreatin treatment and duodenal or ileal lipase outputs, but the number of patients studied is small. Discussion We have shown that treatment of pancreatic steatorrhoea with enteric coated pancreatin increases intestinal enzyme output and improves fat absorption. We have also found that this treatment does not fully reproduce the physiological match that occurs in normal subjects between the amount of luminal enzyme present in a given segment of small bowel and the length of intestine that remains available distal to that segment for digestion and absorption of nutrients. We believe that such an altered relation between enzyme activity and absorptive surface results in wasting of ingested enzyme and 711 contributes to an incomplete correction of the steatorrhoea. Layer et al'2 have shown that postcibal pancreatic enzyme output in healthy volunteers is maximal in the duodenal loop, gradually decreasing along the small bowel. Chyme nutrients are also progressively digested and absorbed. Whereas intraluminal trypsin specific activity remains constant throughout the small bowel, however, the specific activity of lipase decreases rapidly due to its proteolytic degradation Lipolytic activity is barely detectable in the distal ileum, the region where the absorptive capacity of the gut ends. Hence, lipase is a vulnerable enzyme that is conserved precariously even under physiological conditions. In our present studies we have shown that patients with pancreatic steatorrhoea have profoundly depressed duodenal enzyme outputs (as expected due to their exocrine insufficiency). Interestingly, however, these patients maintain a normal downward gradient of luminal enzymatic activity along the small bowel, at least for trypsin. Thus postcibal ileal trypsin output in our patient group amounted to about 5Q% of duodenal output, which is a similar proportion to that of the healthy controls. Because in pancreatic insufficiency lipase secretion is usually impaired to a greater extent than trypsin'6 and, moreover, in our patients proteolytic activity was present along the entire small bowel, it was not altogether unexpected to find that in six out of our eight patients lipase activity had become totally exhausted before chyme reached the distal ileum. A key implication of such a finding is that patients with pancreatic steatorrhoea fail to utilise the entire length of their small bowel for fat digestion and absorption. It follows that if more lipase could be delivered into the small bowel of these patients or if it could be protected better from proteolytic degradation there should still be intestinal surface reserve available for handling their usual dietary lipid load. Enteric coated pancreatin partially achieves the goal of increasing intestinal enzyme activity as previously shown,20 but in a somewhat inefficient manner, for reasons that become apparent from the analysis of our data. Firstly, we found that enteric coated pancreatin increased both duodenal and ileal enzyme output discretely and to a similar extent. Yet the duodenum receives a much higher nutrient load than the distal small bowel and duodenal chyme must still progress through most of the absorptive surf
Recommended
View more...
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks
SAVE OUR EARTH

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!

x